Humanigen (HGEN) Gets a Hold from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Hold rating on Humanigen (HGENResearch Report). The company’s shares closed last Friday at $0.36.

According to TipRanks, Pantginis is an analyst with an average return of -17.8% and a 33.16% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and PDS Biotechnology.

Currently, the analyst consensus on Humanigen is a Hold with an average price target of $1.50.

See the top stocks recommended by analysts >>

HGEN market cap is currently $25.64M and has a P/E ratio of -0.15.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the developing next-generation cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

Read More on HGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More